Form 4: Rapport Therapeutics Director Receives Stock Options

Director Steven M. Paul was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Steven M. Paul received a grant of 15,200 stock options.
• The options have an exercise price of $35.21 per share.
• The grant date is June 10, 2026, with an expiration date of June 10, 2036.
• Vesting occurs on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.21 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Stock Options, Insider Transaction, Director Compensation